Natera, Inc. (NTRA) is retreating this Monday, last changing hands at $298.77 on the NASDAQ. That is a $20.32 decline from the prior close of $319.09 and takes the stock back below the $300 mark. The slide extends a pullback that has now erased a large share of the autumn rally. NTRA sits roughly 31.7% below its 52-week high of $437.41, reached on October 6, 2026, a little more than a month ago. The stock remains about 65% above the bottom of its 52-week range at $181.00, so much of the past year's gain is still intact. Even so, the speed of the retreat from the October peak has changed the tone around the name.
Volume so far in the session is about 427,295 shares, against a 90-day average of roughly 1.58 million. With the regular session still open, turnover is running at about 27% of a typical full day.
Why Natera, Inc. Price is Moving Lower
The pressure traces back to Natera's Q3 report on November 5. The market is still working through what it means for the company's path to profitability. Revenue was the strong part of the release. Q3 sales reached $794.0 million, up 34.1% year over year and well above the roughly $707.5 million analysts expected.
The bottom line did not keep pace. Natera posted a GAAP loss of $0.42 per share, wider than the roughly $0.28 consensus estimate. On the same day, the company announced that Solomon Moshkevich would replace Steve Chapman as CEO. The combination of a profit miss and a leadership change produced a 14.6% drop in the shares on November 6. The stock slipped another 1.19% to $319.09 on November 13. Today's decline continues that reassessment rather than starting a new one.
The details of the quarter explain why the revenue beat has not been enough to steady the stock. The net loss did narrow year over year, from $87.5 million, or $0.64 per share, to $59.9 million, or $0.42. However, operating expenses climbed 19.5% to $576.1 million, and management attributed the increase to hiring and clinical-trial costs.
Management raised full-year 2026 revenue guidance to between $3.005 billion and $3.035 billion. The same outlook calls for up to $1.3 billion in SG&A and $925 million in R&D. That signals spending will stay heavy as the top line expands, and investors are now pricing in a longer wait for consistent profitability under new leadership.
The broader Health Care tape offers little cushion. Moderna, Inc. (MRNA) is down 3.54% and Revolution Medicines, Inc. (RVMD) is off 2.25%. Still, NTRA's decline is notably steeper than either, which points to stock-specific selling.
What is the Natera, Inc. Rating - Should I Sell?
Weiss Ratings assigns NTRA a D- rating. The rating was upgraded on 12/26/2023. Current recommendation is Sell. The rating has held at D- since that upgrade nearly three years ago, despite the company's rapid revenue expansion. That tells investors the risk profile has not improved enough to change the overall verdict. The D- reflects a business with real commercial momentum and a sound balance sheet, but no demonstrated ability yet to turn that momentum into earnings.
The case for Natera rests on its top line and its finances. Natera is rated Good on the Growth Index, supported by 34.08% revenue growth and a sequential step from $752.75 million in the June quarter to $793.98 million in the September quarter. That is unusual scale-up for a diagnostics company already generating close to $3 billion a year. The Growth Index stops short of Excellent because the expansion has not yet translated into earnings. The Excellent rating on the Solvency Index matters for the same reason. Spending plans of $1.3 billion in SG&A and $925 million in R&D only make sense for a company whose balance sheet can fund ongoing losses without strain. The Excellent rating on the Total Return Index reflects how far shareholders have been carried over the past year. Even after today's decline, the stock is still about 65% above its 52-week low.
Where the picture turns is profitability. Natera is rated Very Weak on the Efficiency Index. A -5.66% profit margin and trailing EPS of -$1.14 show that each new dollar of revenue is still being absorbed by operating costs. The third-quarter jump in operating expenses to $576.1 million suggests that dynamic is not about to reverse. A negative forward P/E of -279.17 tells the same story from the valuation side: the market is paying for future earnings that have yet to arrive.
The Fair rating on the Volatility Index reflects recent trading. The stock has fallen 14.6% in a single session after earnings, slid another 6.37% today, and given back about 31.7% from an October high. Those swings illustrate why that index is not rated higher.
Within the Health Care sector, Natera sits alongside Moderna, Inc. (MRNA, D-), Revolution Medicines, Inc. (RVMD, D-), and Roivant Sciences Ltd. (ROIV, D-). It trails IQVIA Holdings Inc. (IQV, D+) and Zoetis Inc. (ZTS, D+), both of which carry somewhat better risk/reward profiles in Weiss's framework. The cluster of D-range ratings across the group shows that sector membership offers Natera little cover.
About Natera, Inc.
Natera, Inc. (NTRA) is a Health Care company that develops and commercializes molecular testing services worldwide. Founded in 2003 as Gene Security Network, LLC, and renamed Natera in January 2012, the company is headquartered in Austin, Texas.
Its oncology franchise is anchored by Signatera, a personalized circulating tumor DNA blood test. Signatera is used for minimal residual disease assessment, early recurrence monitoring, and evaluating treatment response in patients previously diagnosed with cancer. Natera builds on that franchise with Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue-based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Natera's other major pillar is women's health. Panorama, its non-invasive prenatal test, is complemented by Horizon for carrier screening. The company also offers Fetal Focus and Vistara, single-gene NIPTs that screen for 21 and 25 inherited conditions, respectively, and Anora, which analyzes miscarriage tissue for women who have experienced pregnancy loss. In organ health, Prospera assesses active rejection in solid organ transplant recipients, and Renasight provides a kidney gene panel.
Natera reaches its customers through several channels. Its direct sales force and laboratory distribution partners serve independent and reference laboratories, medical centers, physician practices, research laboratories, and pharmaceutical companies. Its Constellation cloud-based software lets licensees run Natera's assays under a distribution model. The NateraCore platform, phlebotomy services, and EMR integration help embed its tests in clinical workflows. A partnership with BGI Genomics Co., Ltd. extends its reach in developing and commercializing NGS-based assays.
Together, a broad test menu spanning oncology, reproductive health, and transplant medicine gives Natera multiple growth avenues. Integration into provider systems adds a degree of stickiness that is difficult for narrower competitors to match.
Investor Outlook
Natera, Inc. (NTRA) carries a Weiss Rating of D- (Sell). Its strong revenue growth has so far been matched by rising costs and a leadership transition that adds uncertainty to the profitability timeline. Investors should watch whether operating expense growth moderates against the raised $3.005 billion to $3.035 billion revenue outlook, and how Solomon Moshkevich frames spending priorities in his first quarters as CEO. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--